Biomira Inc. said Monday it has received regulatory approvalfor clinical trials of its Tru-Scint cancer in vivo diagnosticproducts in Germany.

Oncologists and nuclear medicine specialists will conductpatient testing at 12 cancer centers and hospitals throughoutGermany to determine the safety and efficacy of the products,the Edmonton, Alberta, company (ASE:BRA) said. The productsto be tested are Tru-Scint AD for detecting breast and ovaryadenocarcinomas, Tru-Scint SQ for squamous cell cancers (lung,cervix, head and neck), and Tru-Scint OV for ovarian cancer.

(c) 1997 American Health Consultants. All rights reserved.